SEARCH

SEARCH BY CITATION

References

  • 1
    Sharma VK, Li B, Khanna AS, Sehajpal PK, Suthanthiran M. Which way for drug mediated immunosuppression? Curr Opin Immunol 1994; 6: 784790.
  • 2
    Gonwa TA, Mai ML, Melton LLB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Risk of development and treatment. Transplantation 2001, 72: 1934939.
  • 3
    Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931940.
  • 4
    Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh JW, Reyes J, et al. Comparative incidence of de novo non-lymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 11931200.
  • 5
    2003 Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients Annual Report: Transplant Data 1993–2002. US Department of Health and Human Services, Health Resources and Services Administration, Special Programs Bureau, Division of Transplantation; United Network of Organ Sharing; University Renal Research and Education Association (Table 9.6). Available at: http://www.ustransplant.org/cgi-bin/ar?p=data_tables_10.htm&y=2003.
  • 6
    Kaufman D, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: practice and trends. Am J Transplant 2004; 4(Suppl 9): 3853.
  • 7
    Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519560.
  • 8
    Kahan BD, Ghobrial R. Immunosuppressive agents. Surg Clin North Am 1994; 74: 1029.
  • 9
    Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K, et al. Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg 1994; 220: 297330.
  • 10
    Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, McMichael JP, et al. The Pittsburgh randomized trial of tacrolimus vs. cyclosporin for liver transplantation. J Am Coll Surg 1996; 183: 117125.
  • 11
    European FK 506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423428.
  • 12
    U.S. Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporin for immunosuppression in liver transplantation. N Eng J Med 1994; 331: 11101115.
  • 13
    Sigal NH, Dumont F, Durette P, Siekierka JJ, Peterson L, Rich DH, et al. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med 1991; 173: 619628.
  • 14
    Hong F, Lee J, Piao YJ, Jae YK, Kim YJ, Oh C, et al. Transgenic mice overexpressing cyclophilin A are resistant to cyclosporin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity. Biochem Biophys Res Commun 2004; 316: 10731080.
  • 15
    Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595599.
  • 16
    Morgan JA. The influence of cortisone on the survival of homografts of skin in the rabbit. Surgery 1951; 30: 506515.
  • 17
    Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385395.
  • 18
    Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268: 13151323.
  • 19
    Jain AB, Fung JJ, Todo S, Alessiani M, Takaya S, Abu-Elmagd K, et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK506. Transplant Proc 1991; 23: 928930.
  • 20
    Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57: 685694.
  • 21
    Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657662.
  • 22
    Bonnefoy-Bernard N, Verrier B, Vincent C, Revillard JP. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal antithymocyte globulins. Immunology 1992; 77: 6167.
  • 23
    Mueller TM. Thymoglobulin: an immunologic overview. Curr Opin Organ Transplant 2003; 8: 305312.
  • 24
    Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7: 693697.
  • 25
    Tector AJ, Fridell JA, Mangus S, Shah A, Milgrom ML, Kwo P, et al. Promising early results using delayed introduction of tacrolimus and rabbit anti-thymocyte globulin in adult liver transplant recipients. Liver Transpl 2004; 10: 404407.
  • 26
    Tchervenkov J, Barkun J, Cantarovich M, Tzimas GN, Paraskevas S, Deschenes M, et al. The impact of pretransplant renal function and delayed introduction of calcineurin inhibitors in liver transplantation. [Abstract #350]. Am J Transplant 2003; 3: 241.
  • 27
    Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 15021510.
  • 28
    Kung P, Goldstein G, Reinherz E, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347349.
  • 29
    Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987; 43: 9195.
  • 30
    Fung JJ, Demetris AJ, Porter KA, Iwatsuki S, Gordon RD, Esquivel CO, et al. Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron 1987; 46(Suppl 1): 1933.
  • 31
    Farges O, Ericzon BG, Bresson-Hadni S, Lynch SV, Hockerstedt K, Houssin D, et al. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation 1994; 58: 891898.
  • 32
    Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, et al. The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol 1995; 3: 212221.
  • 33
    Wright A, Shin SU, Morrison SL. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 1992; 12: 125168.
  • 34
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. The Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338; 161165.
  • 35
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Souhillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 11931198.
  • 36
    Tkaczuk J, Yu CL, Baksh S, Milford EL, Carpenter CB, Surakoff SJ, McKay DB. Effect of anti-IL-2Rα antibody on IL-2-induced Jak/STAT signaling. Am J Transplant 2002; 2: 3140.
  • 37
    Kovarik JM, Nashan B, Neuhaus P, Clavien PA, Gerbeau C, Hall ML, Korn A. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 2001; 69: 201209.
  • 38
    Moser AJM. Options for induction immunosuppression in liver transplant recipients. Drugs 2002; 62: 9951011.
  • 39
    Reding R, Vraux H, de Ville de Goyet J, Sokal E, de Hemptinne B, Latinne D, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993; 55: 534541.
  • 40
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transplant 2001; 7: 220225.
  • 41
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young Cet al. The safety and efficacy of a two-dose daclizumab induction therapy in liver transplant patients. Transplantation 2000; 69: 18671872.
  • 42
    Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG. Experience with daclizumab in liver transplantation; renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69: 307311.
  • 43
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrietta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 123131.
  • 44
    Neuhaus P, Clavien PA, Kittur D, Salizonni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132142.
  • 45
    Kwekkeboom J, Warle MC, Rietveld J, Segeren KC, Tilanus HW, Metselaar HJ. Blockade of intragraft IL-2 receptor-alpha by basiliximab is insufficient to prevent activation of liver graft infiltrating cells. Transpl Immunol 2003; 11: 15.
  • 46
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (Basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004; 10: 728733.
  • 47
    Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003; 63: 12291243.
  • 48
    Calne RY. Prope tolerance: a step in the search for tolerance in the clinic. World J Surg 2000; 24: 793796.
  • 49
    Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al. Prope tolerance, perioperative Campath 1H, and low dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 17011702.
  • 50
    Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, et al. Results from a human renal allogaft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 2003; 76: 120129.
  • 51
    Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, et al. Preliminary experience with Alemtuzumab (Campath-1H) and low-dose Tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 12091214.
  • 52
    Knechtle SJ, Pirsch JD, Fechner J Jr, Becker BN, Friedl A, Colvin RB, et al. Campath-1H induction plus rapamycin monotherapy in renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722730.
  • 53
    Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1991; 54: 285294.
  • 54
    Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001; 41: 268276.
  • 55
    Barkmann A, Nashan B, Schmidt HH, Boker KH, Emmanouilidis N, Rosenau J, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69: 18861890.
  • 56
    Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66: 13951398.
  • 57
    Fulton B, Markham A. Mycophenolate Mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278298.
  • 58
    Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA, Kimball PM, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998; 66: 16161621.
  • 59
    Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001; 357: 587591.
  • 60
    Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609610.
  • 61
    Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 6: 473484.
  • 62
    Sala-Prato M, Assalian A, Mehdi AZ, Duperre J, Thompson P, Brazeau P. Inhibition of rapamycin of PDGF- and TGF-β induced human tenon fibroblast proliferation in vitro. J Glaucoma 1995; 5: 5459.
  • 63
    Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35(Suppl 3A): 193S200S.
  • 64
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporin. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 10361042.
  • 65
    King-Biggs MB, Cunitz JM, Park SJ, Savik SK, Hertz MI. Airway anastomotic dehiscence associated with the use of sirolimus immediately after lung transplantation. Transplantation 2003, 75: 14371443.
  • 66
    Van Gelder T, Ter Menlen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003, 75: 788791.
  • 67
    MacDonald AS for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of sirolimus/cyclosporin regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271280.
  • 68
    Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 12151220.
  • 69
    Wiesner R, Klintmalm G, McDiarmid S, the Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. [Abstract]. Am J Transplant 2002; 2: 464.
  • 70
    Wiesner R, for the Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low-dose tacrolimus versus tacrolimus in de novo orthotopic liver transplant recipients. Results from a pilot study. [Abstract]. Hepatology 2002; 36: 208A.
  • 71
    Fung JJ, Marcos A. Rapamycin. Friend, foe or misunderstood? Liver Transpl 2003; 9: 469472.
  • 72
    Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505509.
  • 73
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376377.
  • 74
    McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701708.
  • 75
    Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343351.
  • 76
    Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with wound dehiscence or hepatic artery thrombosis. Liver Transpl 2002; 9: 463468.
  • 77
    Fracavilla A, Carr GI, Starzl TE, Azzarone A, Carrieri G, Zeng GH. Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology 1992; 15: 871877.
  • 78
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 10791085.
  • 79
    Zhu J, Wu, J, Frizell E, Liu SL, Bashey R, Rubin R, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 11981204.
  • 80
    Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 14001406.
  • 81
    Levy G, Moeller V, Jaffe J, Punch J, Mayer D, Neuhaus P. A multi-center, randomized, placebo-controlled, double-blind, parallel group, dose-finding study to evaluate the safety, tolerability and pharmacokinetics of everolimus (E) in de novo liver transplant recipients: 12 and 36 month analysis. [Abstract #94]. Am J Transplant 2004; 4(Suppl 8): 266.
  • 82
    Jin MB, Nakayama M, Ogata T, Fujita M, Mino K, Taniguchi M, et al. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery 2000; 132: 7279.
  • 83
    Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong A, Waldman WJ. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71: 170174.
  • 84
    Savikko J, von Willenbrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effects: potential application for restenosis and chronic rejection. Transplantation 2003; 76: 455458.
  • 85
    Vanrenterghem Y, van Hoof JP, Klinger M, Woldarczk Z, Squifflet J-P, Mourad G, et al. The effects of FK778 in combination with Tacrolimus and steroids: a phase 2 multicenter study in renal transplant patients. Transplantation 2004; 78: 914.
  • 86
    O'Shea JJ. Jaks, STATs, cytokine signal transduction and immunoregulation: are we there yet? Immunity 1997; 7: 111.
  • 87
    Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298: 16301634.
  • 88
    Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875878.
  • 89
    Saemann MD, Zeyda M, Diakos C, Szakeres A, Bohmig GA, Kelemen P, et al. Suppression of early T-cell receptor triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003; 75: 18641872.
  • 90
    Brinkmann V, Cyhster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 10191025.
  • 91
    Anselmo DM, Amersi FF, Shen XD, Gao F, Katori M, Lassman C, et al. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2002; 2: 843849.
  • 92
    Yamada A and Sayegh MH. The CD154-CD40 costimulatory pathway in transplantation. Transplantation 2002; 73(Suppl): S36S39.
  • 93
    Kirk AD, Burkly LC, Batty DS, Baumartner RE, Berning JD, Buchanan K, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686693.
  • 94
    Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 281: 434438.
  • 95
    Knechtle SJ, Hamawy MM, Hu H, Fechner JH Jr, Cho CS. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 2001; 183: 205213.
  • 96
    Koyama I, Kawai T, Andrews D, Boskovic S, Nadazdin O, Wee SL, et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460462.
  • 97
    Vincenti F, Muehlbacher F, Nashan B, Larsen C, Atillasoy E, Natarajan K, Charpentier B, and the LEA29Y Study Group. Co-stimulatory blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety. [Abstract #1037]. Am J Transplant 2004; 4(Suppl 8): 442.
  • 98
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and sign 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 12981302.
  • 99
    Bartlett AS, McCall JL, Ameratunga R, Howden B, Ramadas R, Yeong M-L, et al. Intragraft gene and protein expression in rat liver allografts treated with costimulatory blockade alone or in combination with CyA. J Surg Res 2003; 115: 18.
  • 100
    Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporin. Transplantation 2002; 74: 10701076.
  • 101
    Knechtle SJ, Pirsch JD, Fechner JH, Becker BN, Friedl A, Colvin RB, et al. Campath-1H induction plus rapamycin monotherapy in renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722730.